Sodium-glucose cotransporter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

被引：0
|
作者：
de Carvalho, Mauricio [1 ,2 ]
Heilberg, Ita Pfeferman [3 ]
机构：
[1] Pontif Univ Catol Parana, Fac Med, Escola Med, Curitiba, PR, Brazil
[2] Univ Fed Parana, Dept Clin Med, Curitiba, PR, Brazil
[3] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil
来源：
JORNAL BRASILEIRO DE NEFROLOGIA | 2024年 / 46卷 / 03期
关键词：
Nephrolithiasis; Kidney Calculi; Sodium-Glucose Transporter 2 Inhibitors;
D O I：
10.1590/2175-8239-JBN-2023-0146en
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Role of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
    Lusk, Kathleen A.
    Barnes, Nicole E.
    US PHARMACIST, 2016, 41 (11) : 38 - 42
  • [2] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke
    Kimura, Genjiro
    CIRCULATION JOURNAL, 2017, 81 (06) : 898 - 898
  • [3] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke - Reply
    Kaku, Kohei
    Lee, Jisoo
    Kaspers, Stefan
    Woerle, Hans J.
    George, Jyothis T.
    CIRCULATION JOURNAL, 2017, 81 (06) : 899 - 899
  • [4] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
    Kalra S.
    Cardiology and Therapy, 2016, 5 (2) : 161 - 168
  • [5] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
    Jasleen, Bains
    Vishal, Gupta K.
    Sameera, Malepati
    Fahad, Molla
    Brendan, O'Brien
    Deion, Santander
    Pemminati, Sudhakar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [6] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
    Andreea, Munteanu Madalina
    Surabhi, Swarnkar
    Razvan-Ionut, Popescu
    Lucia, Ciobotaru
    Camelia, Nicolae
    Emil, Tufanoiu
    Tiberiu, Nanea Ioan
    MEDICINA-LITHUANIA, 2023, 59 (04):
  • [7] Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
    Sanjay Kalra
    Rakesh Sahay
    Manash P. Baruah
    Cardiology and Therapy, 2016, 5 (2) : 169 - 169
  • [8] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Marques Vidas, Maria De San Miguel
    Lopez, Paula
    Sanchez Briales, Paula
    Sanchez, Ana
    Lopez Illazquez, Maria Victoria
    Maria Portoles, Jose
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1043 - I1043
  • [9] Sodium-glucose cotransporter 2 (SGLT2) inhibitors-induced erythropoiesis and cardiovascular events in chronic kidney patients
    Vidas, Maria De San Miguel Marques
    Lopez, Paula
    Briales, Paula Sanchez
    Sanchez, Ana
    Illazquez, Maria Victoria Lopez
    Portoles, Jose Maria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [10] Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
    Cao, Min-Jia
    Liang, Ting-Ting
    Xu, Li
    Shi, Fang-Hong
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01):
12345